• Oragenics received an NYSE American deficiency letter on Aug. 26 for failing stockholders’ equity continued listing standards.
• Notice cited Sections 1003(a)(ii) and 1003(a)(iii), tied to equity thresholds for issuers with multi-year operating losses.
• Company has 45 days to submit a compliance plan; acceptance would allow continued listing during a cure period.
• Delisting procedures could start if the plan is not submitted, not accepted, or compliance is not restored by Feb. 25, 2028.
• Separately, FDA provided responses to a Type B meeting package; Oragenics still targets an IND submission by end-2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oragenics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608281625PRIMZONEFULLFEED9817917) on August 28, 2026, and is solely responsible for the information contained therein.